ATE420946T1 - Erzeugung dendritischer zellen aus monozytischen dendritischen vorläuferzellen mit gm-csf ohne anwesenheit zusätzlicher zytokine - Google Patents

Erzeugung dendritischer zellen aus monozytischen dendritischen vorläuferzellen mit gm-csf ohne anwesenheit zusätzlicher zytokine

Info

Publication number
ATE420946T1
ATE420946T1 AT04715780T AT04715780T ATE420946T1 AT E420946 T1 ATE420946 T1 AT E420946T1 AT 04715780 T AT04715780 T AT 04715780T AT 04715780 T AT04715780 T AT 04715780T AT E420946 T1 ATE420946 T1 AT E420946T1
Authority
AT
Austria
Prior art keywords
cells
csf
monocytes
dendritic
dendritic cells
Prior art date
Application number
AT04715780T
Other languages
English (en)
Inventor
Benjamin A Tjoa
Marnix Bosch
Original Assignee
Northwest Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics Inc filed Critical Northwest Biotherapeutics Inc
Application granted granted Critical
Publication of ATE420946T1 publication Critical patent/ATE420946T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/70—Non-animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/10—Mineral substrates
    • C12N2533/12—Glass

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT04715780T 2003-02-27 2004-02-27 Erzeugung dendritischer zellen aus monozytischen dendritischen vorläuferzellen mit gm-csf ohne anwesenheit zusätzlicher zytokine ATE420946T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45101503P 2003-02-27 2003-02-27

Publications (1)

Publication Number Publication Date
ATE420946T1 true ATE420946T1 (de) 2009-01-15

Family

ID=32927693

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04715780T ATE420946T1 (de) 2003-02-27 2004-02-27 Erzeugung dendritischer zellen aus monozytischen dendritischen vorläuferzellen mit gm-csf ohne anwesenheit zusätzlicher zytokine

Country Status (20)

Country Link
US (4) US8389278B2 (de)
EP (1) EP1604016B1 (de)
JP (1) JP4762887B2 (de)
KR (2) KR101201875B1 (de)
CN (1) CN1784488B (de)
AT (1) ATE420946T1 (de)
AU (2) AU2004214896A1 (de)
BR (1) BRPI0407900A (de)
CA (1) CA2517295C (de)
CY (1) CY1109099T1 (de)
DE (1) DE602004019057D1 (de)
DK (1) DK1604016T3 (de)
ES (1) ES2321939T3 (de)
IL (1) IL170512A (de)
MX (1) MXPA05009178A (de)
NZ (1) NZ542071A (de)
PL (1) PL209998B1 (de)
RU (1) RU2364625C2 (de)
TW (1) TW200506061A (de)
WO (1) WO2004076651A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040057935A1 (en) * 2002-09-20 2004-03-25 Cedars-Sinai Medical Center Intratumoral delivery of dendritic cells
CN102600461B (zh) * 2002-12-06 2017-07-14 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤
EP1670513B1 (de) * 2003-10-06 2013-01-23 Cedars-Sinai Medical Center Cox-2-inhibitoren und dendritische zellen zur verwendung in der krebsbehandlung
JP5015601B2 (ja) * 2003-10-21 2012-08-29 セダーズ−シナイ メディカル センター 中枢神経系の癌を含む癌の処置のための系および方法
US7790039B2 (en) * 2003-11-24 2010-09-07 Northwest Biotherapeutics, Inc. Tangential flow filtration devices and methods for stem cell enrichment
JP5020935B2 (ja) 2005-04-08 2012-09-05 アルゴス セラピューティクス，インコーポレイティド 樹状細胞組成物および方法
KR20220113543A (ko) * 2005-12-08 2022-08-12 노쓰웨스트 바이오써라퓨틱스, 인크. 미성숙 단핵구성 수지상 세포의 활성화를 유도하기 위한 조성물 및 방법
EP1806395A1 (de) * 2006-01-06 2007-07-11 Stichting Sanquin Bloedvoorziening Maturation von dendritischen Zellen
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
CA2700436C (en) 2006-09-28 2017-04-18 John S. Yu Cancer vaccines and vaccination methods
PL1920781T3 (pl) * 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
KR100896747B1 (ko) 2007-05-30 2009-05-11 동아대학교 산학협력단 후코이단 또는 그 유사체를 함유하는 수지상 세포의 성숙화유도용 조성물
US8728465B2 (en) * 2008-06-17 2014-05-20 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
PL2328923T3 (pl) 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
JP2010063404A (ja) * 2008-09-10 2010-03-25 Olympus Corp 幹細胞の分離方法
FR2940451B1 (fr) * 2008-12-18 2014-09-12 Proteus Procede d'evaluation de l'immunogenicite des proteines
EP2427485B1 (de) * 2009-05-07 2016-12-07 ImmunoCellular Therapeutics, Ltd. Cd133-epitope
WO2011011688A2 (en) * 2009-07-24 2011-01-27 Rhode Island Hospital DENDRITIC CELL VACCINES FOR ASPARAGINYL- β - HYDROXYLASE EXPRESSING TUMORS
CA2777400C (en) 2009-10-12 2018-11-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Granulysin in immunotherapy
RU2575978C2 (ru) * 2010-03-15 2016-02-27 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Система и способ получения и хранения активированных зрелых дендритных клеток
RU2458985C1 (ru) * 2011-03-18 2012-08-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт клинической иммунологии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИКИ" СО РАМН) Способ генерации антиген-специфических цитотоксических клеток с противоопухолевой активностью
DE13746292T1 (de) * 2012-02-10 2014-10-30 Hakushinkouseikai Foundation Proliferationsmittel für monozyten, kulturmedium zur proliferation von monozyten, verfahren zur herstellung von monozyten, verfahren zur herstellung dendritischer zellen und verfahren zur herstellung eines impfstoffs mit dendritischen zellen
ES2662333T3 (es) 2013-02-14 2018-04-06 Immunocellular Therapeutics Ltd. Vacunas contra el cáncer y métodos de vacunación
WO2016011878A1 (zh) * 2014-07-23 2016-01-28 国家纳米科学中心 一种抑制肿瘤转移和治疗白血病的多肽和多肽复合物、其制备方法及其应用
CN104098652B (zh) * 2014-07-23 2016-11-09 国家纳米科学中心 一种抑制肿瘤转移的多肽和多肽复合物、其制备方法及其应用
IL256522B2 (en) * 2015-06-30 2024-10-01 Northwest Biotherapeutics Inc Optimally activated dendritic cells that result in an enhanced or enhanced antitumor immune response
RU2749610C2 (ru) * 2015-09-15 2021-06-16 Нортвест Байотерапьютикс, Инк. Способы, относящиеся к композициям активированных дендритных клеток и к иммунотерапевтическому лечению индивидуумов с прогрессирующим раком
CN105483084A (zh) * 2016-01-04 2016-04-13 英普乐孚生物技术(上海)有限公司 肿瘤抗原靶向性dc细胞的制备方法
EP3810641A4 (de) 2018-06-19 2022-07-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Durch onkolytisches virus oder antigenpräsentierende zellen vermittelte krebstherapie unter verwendung von typ-i-interferon und cd40-ligand
KR102159766B1 (ko) * 2018-11-12 2020-09-24 조선대학교산학협력단 홍조류추출물을 이용한 미성숙수지상세포 분화유도용 배지조성물 및 미성숙수지상세포 분화유도방법
EP3945815A4 (de) * 2019-04-03 2023-04-19 Akron Biotechnology, LLC Kryokonservierung und zellkulturmedien
US20220273709A1 (en) * 2019-07-12 2022-09-01 Kyushu University, National University Corporation Development of therapy for improving myocardial contraction and method for inhibiting cardiomyocyte death
EP4061423A4 (de) * 2019-11-18 2023-12-06 Children's Medical Center Corporation Hyperaktive dendritische zellen für dauerhafte antitumorwirkung auf adoptiver zelltransferbasis
KR102904431B1 (ko) * 2021-05-07 2025-12-26 (주)나노팬텍 수지상 세포의 배양 방법
US20240207308A1 (en) * 2021-05-07 2024-06-27 NANOFAENTECH CO., Ltd. Method for culturing dendritic cells
CN113881632B (zh) * 2021-09-29 2023-09-29 四川省医学科学院·四川省人民医院 一种提高dc细胞活性的细胞培养基及培养方法
US12584107B2 (en) * 2022-01-20 2026-03-24 3T Biosciences, Inc. T cell receptor (TCR) compositions and methods for optimizing antigen reactive T-cells
US20230287080A1 (en) * 2022-01-20 2023-09-14 3T Biosciences, Inc. T cell receptor (tcr) compositions and methods for optimizing antigen reactive t-cells
GB2624871A (en) * 2022-11-29 2024-06-05 Alv B As Process for preparing a population of dendritic cells and immunotherapy using the same
CN118389430A (zh) * 2024-04-12 2024-07-26 广东壹加再生医学研究院有限公司 一种高抗肿瘤特异性dc-cik细胞的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3683956D1 (de) * 1985-06-11 1992-04-02 Us Commerce In einem serumfreien medium in suspension kultivierte humane monozyten.
US5162504A (en) * 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
DE69333433T2 (de) 1992-04-01 2004-12-02 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
US6010905A (en) * 1995-01-27 2000-01-04 The United States Of America As Represented By The Department Of Health & Human Services Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US7659119B2 (en) * 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
US20020094545A1 (en) 2000-11-30 2002-07-18 Harris Paul E. Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
AU2002326463A1 (en) * 2001-07-25 2003-02-17 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
CA2459713C (en) * 2001-09-06 2015-08-18 Northwest Biotherapeutics, Inc. Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response
CN1713951B (zh) * 2002-06-19 2010-05-26 西北生物治疗药物公司 切向流过滤设备和白细胞富集方法
MXPA05008486A (es) * 2003-02-10 2005-11-17 Northwest Biotherapeutics Inc Celulas presentadoras de antigeno cd14+ cultivadas.

Also Published As

Publication number Publication date
AU2010201319A1 (en) 2010-04-29
EP1604016B1 (de) 2009-01-14
JP4762887B2 (ja) 2011-08-31
US20210102169A1 (en) 2021-04-08
WO2004076651A3 (en) 2005-03-10
US20130273654A1 (en) 2013-10-17
US20040203143A1 (en) 2004-10-14
TW200506061A (en) 2005-02-16
ES2321939T3 (es) 2009-06-15
CA2517295C (en) 2016-01-12
PL378291A1 (pl) 2006-03-20
EP1604016A4 (de) 2006-03-08
JP2006519021A (ja) 2006-08-24
WO2004076651A2 (en) 2004-09-10
DE602004019057D1 (de) 2009-03-05
US10731130B2 (en) 2020-08-04
KR20050107471A (ko) 2005-11-11
CY1109099T1 (el) 2014-07-02
NZ542071A (en) 2007-11-30
BRPI0407900A (pt) 2006-03-21
AU2004214896A1 (en) 2004-09-10
RU2364625C2 (ru) 2009-08-20
US11827903B2 (en) 2023-11-28
IL170512A (en) 2013-12-31
PL209998B1 (pl) 2011-11-30
US8389278B2 (en) 2013-03-05
EP1604016A2 (de) 2005-12-14
HK1086597A1 (en) 2006-09-22
CN1784488B (zh) 2010-07-28
MXPA05009178A (es) 2006-03-08
US20160024472A1 (en) 2016-01-28
US9102917B2 (en) 2015-08-11
KR101201875B1 (ko) 2012-11-15
AU2010201319B2 (en) 2012-09-06
CA2517295A1 (en) 2004-09-10
RU2005129561A (ru) 2006-03-10
KR20110106474A (ko) 2011-09-28
DK1604016T3 (da) 2009-05-18
CN1784488A (zh) 2006-06-07

Similar Documents

Publication Publication Date Title
ATE420946T1 (de) Erzeugung dendritischer zellen aus monozytischen dendritischen vorläuferzellen mit gm-csf ohne anwesenheit zusätzlicher zytokine
Peters et al. Signals required for differentiating dendritic cells from human monocytes in vitro
Lu et al. Th9 cells promote antitumor immune responses in vivo
Kadowaki Dendritic cells—a conductor of T cell differentiation—
Jongmans et al. Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: the importance of maturation cocktails
Chen et al. Follicular helper T cells promote liver pathology in mice during Schistosoma japonicum infection
Khosravi et al. Induction of CD4+ CD25+ FOXP3+ regulatory T cells by mesenchymal stem cells is associated with modulation of ubiquitination factors and TSDR demethylation
BRPI0212545B8 (pt) método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t
JP2008535493A5 (de)
Gregori Dendritic cells in networks of immunological tolerance
ATE268812T1 (de) Methode und zusammensetzungen zum erlangen reifer dendritischer zellen
ATE525908T1 (de) Einstufiges schnellverfahren zurherstellung eines antigenbeladenen dendritenzellimpfstoffs aus vorstufen
DE60108661D1 (de) Herstellung und verwendung von dendritischen zellen
Lim et al. Principal role of IL-12p40 in the decreased Th1 and Th17 responses driven by dendritic cells of mice lacking IL-12 and IL-18
AR128929A1 (es) Composiciones y métodos para activar células inmunitarias
Holtick et al. Impact of psoralen/UVA-treatment on survival, activation, and immunostimulatory capacity of monocyte-derived dendritic cells
Son et al. Prostaglandin E2 is a negative regulator on human plasmacytoid dendritic cells
Trujillo-Ocampo et al. IL-7 During Antigenic Stimulation Using Allogeneic Dendritic Cells Promotes Expansion of CD45RA-CD62L+ CD4+ Invariant NKT Cells With Th-2 Biased Cytokine Production Profile
Vidal et al. Enhanced maturation and functional capacity of monocyte‐derived immature dendritic cells by the synthetic immunomodulator murabutide
Markey et al. Impact of cytokine gene polymorphisms on graft‐vs‐host disease
Pizzurro et al. Cytokine-enhanced maturation and migration to the lymph nodes of a human dying melanoma cell-loaded dendritic cell vaccine
O'Connell et al. Type‐1 polarized nature of mouse liver CD8α–and CD8α+ dendritic cells: tissue‐dependent differences offset CD8α‐related dendritic cell heterogeneity
ATE371722T1 (de) Zusammensetzungen und verfahren zur herstellung von antigen-präsentierenden zellen
Ghaedi et al. Different Doses of Transforming Growth Factor-β on In vitro Differentiation of Human Naïve CD4+ T Cells to T Helper 17
Baumeister et al. G-CSF mobilizes slanDCs (6-sulfo LacNAc+ dendritic cells) with a high proinflammatory capacity

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties